Table 1. Patients Characteristics.
| All N (%) | Non-ALCL ALK+ N (%) | ALCL ALK+ N (%) | P | |
|---|---|---|---|---|
| All patients | 209 (100) | 139 (66) | 70 (34) | |
| Age | ||||
| Median (range) | 49.3 (15–85) | 57.1 (19–85) | 42.6 (15–82) | <0.0001 |
| ≥60 | 69 (33) | 60 (43) | 9 (13) | <0.0001 |
| Gender | ||||
| Male | 128 (61) | 80 (58) | 48 (69) | 0.1228 |
| Histology | ||||
| PTCL-NOS | 67 (32) | 67 (48) | ||
| ALCL ALK positive | 70 (34) | - | 70 (100) | |
| ALCL ALK negative | 36 (17) | 36 (26) | - | |
| AITL | 21 (10) | 21 (15) | - | |
| EATL | 10 (5) | 10 (7) | - | |
| Others | 5 (2) | 5 (4) | - | |
| Ann Arbor Stage | ||||
| III–IV | 143 (68) | 102 (73) | 41 (59) | 0.0297 |
| ECOG PS | ||||
| ≥2 | 87 (42) | 54 (39) | 33 (47) | 0.2464 |
| Serum LDH Level | ||||
| > ULN | 92 (44) | 64 (46) | 28 (40) | 0.3585 |
| Extranodal Sites | ||||
| >1 | 68 (33) | 54 (39) | 14 (20) | 0.0057 |
| Bone marrow involvement | ||||
| Yes | 22 (12)* | 18 (15)** | 4 (7)*** | 0.1153 |
| IPI | ||||
| >2 | 91 (44) | 71 (51) | 20 (29) | 0.0017 |
| PIT | ||||
| >2 | 26 (15)* | 22 (18)** | 4 (7)*** | 0.0392 |
Legend:
* N = 179;
** N = 120;
*** N = 59;
PTCL-NOS: Peripheral T-Cell Lymphoma Not Otherwise Specified; ALCL: Anaplastic Large-Cell Lymphoma; ALK: Anaplastic Large Cell Lymphoma Kinase; EATL: Enteropathy-Associated T-cell Lymphoma; AITL: Angioimmunoblastic T-cell Lymphoma; Others: includes hepatosplenic T-cell lymphoma (N = 3) and extranodal T/NK-cell lymphoma nasal type (N = 2);IPI: International Prognostic Index; PIT: Prognostic Index for PTCL-NOS